Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanocrystals- A Substantial Platform for Drug Delivery Applications

Author(s): Akanksha Patel* and Abhay Dharamsi

Volume 11, Issue 4, 2021

Published on: 27 December, 2021

Page: [202 - 212] Pages: 11

DOI: 10.2174/2468187312666211221124154

Price: $65

Open Access Journals Promotions 2
Abstract

Poor solubility of a drug is one of the major concerns in drug delivery. Many strategies have been employed for solving this problem, but there are still some deficiencies with current strategies, such as low drug loading, high toxicity, poor stability, potential drug loss during storage, and complex manufacturing method. By formulating nanocrystals, problems associated with the delivery of drugs with low water or lipid solubility can be addressed. Unlike polymeric nanoparticles and lipidic nanoparticles, they are not reservoir or matrix systems. Nanocrystals are colloidal suspensions of nanosized particles stabilized by polymeric or electrostatic stabilization. They can be prepared by Top-down or Bottom-up approaches. Some of the methods for the preparation of nanocrystals are nanoprecipitation, media milling, high-pressure homogenization, emulsions and microemulsions as templates, supercritical fluid technology, and co-grinding. They can be used for oral, intravenous, ocular, inhalation, intramuscular drug delivery and drug targeting.

Keywords: Nanocrystals, nanosuspension, solubility Enhancement, drug delivery, bioavailability, colloidal dispersion.

« Previous Next »
Graphical Abstract

[1]
Nanjwadea BK, Derkara GK, Bechraa H, Manvi FV. Nanosized technological approaches for the delivery of poorly water soluble drugs. Iran J Pharm Sci 2010; 6: 149-62.
[2]
Thorat YS, Gonjari ID, Hosmani AH. Solubility enhancement techniques: A review on conventional and novel approaches. Int J Pharm Sci Res 2011; 2: 2501-13.
[3]
Thakkar H, Patel B, Thakkar S. A review on techniques for oral bioavailability enhancement of drugs. Int J Pharm Sci Rev Res 2010; 4: 203-23.
[4]
Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 2009; 11(4): 740-6.
[http://dx.doi.org/10.1208/s12248-009-9144-x] [PMID: 19876745]
[5]
Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006; 3(6): 631-43.
[http://dx.doi.org/10.1021/mp0600182] [PMID: 17140251]
[6]
Bajaj H, Bisht S, Yadav M, Singh V. Bioavailability enhancement: A review. Int J Pharm Bio Sci 2011; 2(2): 202-16.
[7]
Gupta AK, Sehrawat SK. Bioavailability enhancement of poorly water soluble drugs: A review. Int J Pharmacy Life Sci 2011; 2: 640-50.
[8]
Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm 2011; 420(1): 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.032] [PMID: 21884771]
[9]
Müller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001; 47(1): 3-19.
[http://dx.doi.org/10.1016/S0169-409X(00)00118-6] [PMID: 11251242]
[10]
Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 2004; 56(7): 827-40.
[http://dx.doi.org/10.1211/0022357023691] [PMID: 15233860]
[11]
Chingunpituk J. Nanosuspension technology for drug delivery. Walailak J Sci Technol 2007; 4: 139-53.
[12]
Wagh KS, Patil SK, Akarte AK, Baviskar DT. Nanosuspension - a new approach of bioavailability enhancement. Int J Pharm Sci Rev Res 2011; 8: 61-5.
[13]
Muller RH, Jacobs C, Kayer O. Nanosuspensions for the formulation of poorly soluble drugs. In: Nielloud F, Marti-Mestres G, Eds. Pharmaceutical emulsion and suspension. New York: Marcel Dekker 2000; pp. 383-407.
[http://dx.doi.org/10.1201/b14005-13]
[14]
Sharma P, Garg S. Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 2010; 62(4-5): 491-502.
[http://dx.doi.org/10.1016/j.addr.2009.11.019] [PMID: 19931328]
[15]
Shegokar R, Müller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010; 399(1-2): 129-39.
[http://dx.doi.org/10.1016/j.ijpharm.2010.07.044] [PMID: 20674732]
[16]
Pu X, Sun J, Li M, He Z. Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs. Curr Nanosci 2009; 5: 417-27.
[http://dx.doi.org/10.2174/157341309789378177]
[17]
Patel DJ, Patel JK. Mucoadhesive effect of polyethyleneoxide on famotidine nanosuspension prepared by solvent evaporation method. Int J Pharm Pharm Sci 2010; 2: 122-7.
[18]
Chan HK, Kwok PC. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev 2011; 63(6): 406-16.
[http://dx.doi.org/10.1016/j.addr.2011.03.011] [PMID: 21457742]
[19]
Xia D, Quan P, Piao H, et al. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci 2010; 40(4): 325-34.
[http://dx.doi.org/10.1016/j.ejps.2010.04.006] [PMID: 20417274]
[20]
Zhang X, Xia Q, Gu N. Preparation of All-Trans Retinoic Acid nanosuspensions using a modified precipitation method. Drug Dev Ind Pharm 2006; 32(7): 857-63.
[http://dx.doi.org/10.1080/03639040500534184] [PMID: 16908423]
[21]
Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm 2006; 62(1): 3-16.
[http://dx.doi.org/10.1016/j.ejpb.2005.05.009] [PMID: 16129588]
[22]
Junghanns JU, Müller RH, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine 2008; 3(3): 295-309.
[PMID: 18990939]
[23]
Karakucuk A, Celebi N, Teksin ZS. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach. Eur J Pharm Sci 2016; 95: 111-21.
[http://dx.doi.org/10.1016/j.ejps.2016.05.010] [PMID: 27181836]
[24]
Grau MJ, Kayser O, Müller RH. Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. Int J Pharm 2000; 196(2): 155-9.
[http://dx.doi.org/10.1016/S0378-5173(99)00411-1] [PMID: 10699708]
[25]
Krause KP, Müller RH. Production and characterisation of highly concentrated nanosuspensions by high pressure homogenisation. Int J Pharm 2001; 214(1-2): 21-4.
[http://dx.doi.org/10.1016/S0378-5173(00)00626-8] [PMID: 11282231]
[26]
Muller RH, Peters K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int J Pharm 1998; 160: 229-37.
[http://dx.doi.org/10.1016/S0378-5173(97)00311-6]
[27]
Krause KP, Kayser O, Mäder K, Gust R, Müller RH. Heavy metal contamination of nanosuspensions produced by high-pressure homogenisation. Int J Pharm 2000; 196(2): 169-72.
[http://dx.doi.org/10.1016/S0378-5173(99)00414-7] [PMID: 10699711]
[28]
Zhang D, Tan T, Gao L, Zhao W, Wang P. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev Ind Pharm 2007; 33(5): 569-75.
[http://dx.doi.org/10.1080/03639040600975147] [PMID: 17520449]
[29]
Sun W, Mao S, Shi Y, Li LC, Fang L. Nanonization of itraconazole by high pressure homogenization: stabilizer optimization and effect of particle size on oral absorption. J Pharm Sci 2011; 100(8): 3365-73.
[http://dx.doi.org/10.1002/jps.22587] [PMID: 21520089]
[30]
Singare DS, Marella S, Gowthamrajan K, Kulkarni GT, Vooturi R, Rao PS. Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm 2010; 402(1-2): 213-20.
[http://dx.doi.org/10.1016/j.ijpharm.2010.09.041] [PMID: 20933066]
[31]
Patel DJ, Patel JK, Pandya VM. Improvement in the dissolution of poorly water soluble drug using media milling technique. Thaiphesatchasan 2010; 34: 155-64.
[32]
Singh SK, Srinivasan KK, Gowthamarajan K, Singare DS, Prakash D, Gaikwad NB. Investigation of preparation parameters of nanosuspension by top-down media milling to improve the dissolution of poorly water-soluble glyburide. Eur J Pharm Biopharm 2011; 78(3): 441-6.
[http://dx.doi.org/10.1016/j.ejpb.2011.03.014] [PMID: 21439378]
[33]
Ghosh I, Schenck D, Bose S, Ruegger C. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption. Eur J Pharm Sci 2012; 47(4): 718-28.
[http://dx.doi.org/10.1016/j.ejps.2012.08.011] [PMID: 22940548]
[34]
Trotta M, Gallarate M, Pattarino F, Morel S. Emulsions containing partially water-miscible solvents for the preparation of drug nanosuspensions. J Control Release 2001; 76(1-2): 119-28.
[http://dx.doi.org/10.1016/S0168-3659(01)00432-1] [PMID: 11532318]
[35]
Laxmi P. Nanosuspension technology: A review. Int J Pharm Pharm Sci 2010; 2: 1-6.
[36]
Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006; 312(1-2): 179-86.
[http://dx.doi.org/10.1016/j.ijpharm.2006.01.008] [PMID: 16469459]
[37]
Chattopadhyay P, Gupta RB. Production of griseofulvin nanoparticles using supercritical CO(2) antisolvent with enhanced mass transfer. Int J Pharm 2001; 228(1-2): 19-31.
[http://dx.doi.org/10.1016/S0378-5173(01)00803-1] [PMID: 11576765]
[38]
Young TJ, Mawson S, Johnston KP, Henriksen IB, Pace GW, Mishra AK. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol Prog 2000; 16(3): 402-7.
[http://dx.doi.org/10.1021/bp000032q] [PMID: 10835242]
[39]
Paisana MC, Mullers KC, Wahl MA, Pinto JF. Production and stabilization of olanzapine nanoparticles by rapid expansion of supercritical solutions (RESS). J Supercrit Fluids 2016; 109: 124-33.
[http://dx.doi.org/10.1016/j.supflu.2015.11.012]
[40]
Itoh K, Pongpeerapat A, Tozuka Y, Oguchi T, Yamamoto K. Nanoparticle formation of poorly water-soluble drugs from ternary ground mixtures with PVP and SDS. Drug Dev Ind Pharm 2007; 33: 569-75.
[41]
Chingunpitak J, Puttipipatkhachorn S, Chavalitshewinkoon-Petmitr P, Tozuka Y, Moribe K, Yamamoto K. Formation, physical stability and in vitro antimalarial activity of dihydroartemisinin nanosuspensions obtained by co-grinding method. Drug Dev Ind Pharm 2008; 34(3): 314-22.
[http://dx.doi.org/10.1080/03639040701662388] [PMID: 18363147]
[42]
Shudo J, Pongpeerapat A, Wanawongthai C, Moribe K, Yamamoto K. In vivo assessment of oral administration of probucol nanoparticles in rats. Biol Pharm Bull 2008; 31(2): 321-5.
[http://dx.doi.org/10.1248/bpb.31.321] [PMID: 18239296]
[43]
Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 2008; 364(1): 64-75.
[http://dx.doi.org/10.1016/j.ijpharm.2008.07.023] [PMID: 18721869]
[44]
Kesisoglou F, Panmai S, Wu Y. Nanosizing--oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007; 59(7): 631-44.
[http://dx.doi.org/10.1016/j.addr.2007.05.003] [PMID: 17601629]
[45]
Verma S, Kumar S, Gokhale R, Burgess DJ. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm 2011; 406(1-2): 145-52.
[http://dx.doi.org/10.1016/j.ijpharm.2010.12.027] [PMID: 21185926]
[46]
Arunkumar N, Deecaraman M, Rani C. Nanosuspension technology and its applications in drug delivery. Asian J Pharm 2009; 3: 168-73.
[http://dx.doi.org/10.4103/0973-8398.56293]
[47]
Jia L, Wong H, Cerna C, Weitman SD. Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry. Pharm Res 2002; 19(8): 1091-6.
[http://dx.doi.org/10.1023/A:1019829622088] [PMID: 12240933]
[48]
Ghosh S, Chiang PC, Wahlstrom JL, Fujiwara H, Selbo JG, Roberds SL. Oral delivery of 1,3-dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive rats. Basic Clin Pharmacol Toxicol 2008; 102(5): 453-8.
[http://dx.doi.org/10.1111/j.1742-7843.2008.00213.x] [PMID: 18312493]
[49]
Wei L, Yonggang Y, Yongshou T, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm 2011; 375: 107-13.
[50]
Singh MK, Pooja D, Ravuri HG, Gunukula A, Kulhari H, Sistla R. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability. Phytomedicine 2018; 40: 48-54.
[http://dx.doi.org/10.1016/j.phymed.2017.12.021] [PMID: 29496174]
[51]
Xiong R, Lu W, Li J, Wang P, Xu R, Chen T. Preparation and characterization of intravenously injectable nimodipine nanosuspension. Int J Pharm 2008; 350(1-2): 338-43.
[http://dx.doi.org/10.1016/j.ijpharm.2007.08.036] [PMID: 17920794]
[52]
Zhang Z, Zhang X, Xue W, et al. Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line. Int J Nanomedicine 2010; 5: 735-42.
[http://dx.doi.org/10.2147/IJN.S13537] [PMID: 21042419]
[53]
Peters K, Leitzke S, Diederichs JE, et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45(1): 77-83.
[http://dx.doi.org/10.1093/jac/45.1.77] [PMID: 10629016]
[54]
Schöler N, Krause K, Kayser O, et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother 2001; 45(6): 1771-9.
[http://dx.doi.org/10.1128/AAC.45.6.1771-1779.2001] [PMID: 11353624]
[55]
Rabinow B, Kipp J, Papadopoulos P, et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007; 339(1-2): 251-60.
[http://dx.doi.org/10.1016/j.ijpharm.2007.02.030] [PMID: 17398045]
[56]
Epstein H, Berger V, Levi I, et al. Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. J Control Release 2007; 117(3): 322-32.
[http://dx.doi.org/10.1016/j.jconrel.2006.10.030] [PMID: 17234295]
[57]
Wang Z, Li Z, Zhang D, Miao L, Huang G. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery. Drug Deliv 2015; 22(1): 79-85.
[http://dx.doi.org/10.3109/10717544.2013.871600] [PMID: 24401038]
[58]
Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007; 340(1-2): 126-33.
[http://dx.doi.org/10.1016/j.ijpharm.2007.03.011] [PMID: 17600645]
[59]
Pignatello R, Ricupero N, Bucolo C, Maugeri F, Maltese A, Puglisi G. Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene. AAPS PharmSciTech 2006; 7: E1-7.
[http://dx.doi.org/10.1208/pt070127]
[60]
Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002; 23(15): 3247-55.
[http://dx.doi.org/10.1016/S0142-9612(02)00080-7] [PMID: 12102196]
[61]
Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspension. Ophthalmic Res 2002; 34(5): 319-23.
[http://dx.doi.org/10.1159/000065608] [PMID: 12381895]
[62]
Maged A, Mahmoud AA, Ghorab MM. Nano spray drying technique as a novel approach to formulate stable econazole nitrate nanosuspension formulations for ocular use. Mol Pharm 2016; 13(9): 2951-65.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00167] [PMID: 27010795]
[63]
Tuomela A, Liu P, Puranen J, et al. Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo. Int J Pharm 2014; 467(1-2): 34-41.
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.048] [PMID: 24680962]
[64]
Jacobs C, Müller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res 2002; 19(2): 189-94.
[http://dx.doi.org/10.1023/A:1014276917363] [PMID: 11883646]
[65]
Zhang Y, Zhang J. Preparation of budesonide nanosuspensions for pulmonary delivery: Characterization, in vitro release and in vivo lung distribution studies. Artif Cells Nanomed Biotechnol 2016; 44(1): 285-9.
[http://dx.doi.org/10.3109/21691401.2014.944645] [PMID: 25100657]
[66]
Dibaei M, Rouini MR, Sheikholeslami B, Gholami M, Dinarvand R. The effect of surface treatment on the brain delivery of curcumin nanosuspension: in vitro and in vivo studies. Int J Nanomedicine 2019; 14: 5477-90.
[http://dx.doi.org/10.2147/IJN.S199624] [PMID: 31409999]
[67]
Jacobs C, Kayser O, Müller RH. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm 2001; 214(1-2): 3-7.
[http://dx.doi.org/10.1016/S0378-5173(00)00622-0] [PMID: 11282227]
[68]
Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int J Pharm 2004; 275(1-2): 13-7.
[http://dx.doi.org/10.1016/j.ijpharm.2003.10.038] [PMID: 15081134]
[69]
Yamaguchi Y, Nagasawa T, Nakamura N, et al. Successful treatment of photo-damaged skin of nano-scale atRA particles using a novel transdermal delivery. J Control Release 2005; 104(1): 29-40.
[http://dx.doi.org/10.1016/j.jconrel.2004.11.036] [PMID: 15866332]
[70]
Chen X, Lo CYL, Sarkari M, Williams RO, Johnston KP. Ketoprofen nanoparticle gels formed by evaporative precipitation into aqueous solution. AIChE J 2006; 52: 2428-35.
[http://dx.doi.org/10.1002/aic.10848]
[71]
Al Shaal L, Shegokar R, Müller RH. Production and characterization of antioxidant apigenin nanocrystals as a novel UV skin protective formulation. Int J Pharm 2011; 420(1): 133-40.
[http://dx.doi.org/10.1016/j.ijpharm.2011.08.018] [PMID: 21871547]
[72]
Mishra PR, Al Shaal L, Müller RH, Keck CM. Production and characterization of Hesperetin nanosuspensions for dermal delivery. Int J Pharm 2009; 371(1-2): 182-9.
[http://dx.doi.org/10.1016/j.ijpharm.2008.12.030] [PMID: 19162147]
[73]
Liu X, Gan H, Hu C, et al. Silver sulfadiazine nanosuspension-loaded thermosensitive hydrogel as a topical antibacterial agent. Int J Nanomedicine 2018; 14: 289-300.
[http://dx.doi.org/10.2147/IJN.S187918] [PMID: 30643407]
[74]
Karakucuk A, Teksin ZS, Eroglu H, Celebi N. Evaluation of improved oral bioavailability of ritonavir nanosuspension. Eur J Pharm Sci 2019; 131: 153-8.
[http://dx.doi.org/10.1016/j.ejps.2019.02.028] [PMID: 30790704]
[75]
Alshweiat A, Csóka I, Tömösi F, et al. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation. Int J Pharm 2020; 579119166
[http://dx.doi.org/10.1016/j.ijpharm.2020.119166] [PMID: 32084574]
[76]
Na YG, Pham TMA, Byeon JJ, et al. Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor. Int J Pharm 2020; 581119287
[http://dx.doi.org/10.1016/j.ijpharm.2020.119287] [PMID: 32243963]
[77]
Liu Q, Mai Y, Gu X, Zhao Y, Di X, Ma X. A wet-milling method for the preparation of cilnidipine nanosuspension with enhanced dissolution and oral bioavailability. J Drug Deliv Sci Technol 2020; 55101371
[http://dx.doi.org/10.1016/j.jddst.2019.101371]
[78]
Rossi I, Sonvico F, McConville JT, et al. Nebulized coenzyme Q10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. Eur J Pharm Sci 2018; 113: 159-70.
[http://dx.doi.org/10.1016/j.ejps.2017.10.024] [PMID: 29066385]

Rights & Permissions Print Cite
Article Metrics
27
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy